Summary: Among 142 short, prepubertal children born small for gestational age (SGA), weekly somapacitan achieved a week-52 height velocity of 11.0 cm/year versus 9.4 and 11.1 cm/year with two daily growth hormone (GH) doses. Noninferiority was reported against both doses, with superiority only against the lower daily dose; adult height remains unestablished.
PICO Summary
| Element | Detail |
|---|---|
| Population | 142 treatment-naive, prepubertal children with short stature born SGA in the multinational REAL8 phase 3 basket programme, reported across 78 sites in 26 countries. Allocation was 2:1:1; 140 completed the 52-week main period. Exact arm counts were not available in the saved abstract and are not inferred from the allocation ratio. |
| Intervention | Subcutaneous somapacitan 0.24 mg/kg once weekly for the 52-week main phase. This is the trial regimen, not an individual prescribing recommendation. |
| Comparator | Subcutaneous daily GH at 0.035 mg/kg/day or 0.067 mg/kg/day. These are two separate active comparator arms and must not be combined when interpreting superiority. |
| Outcomes | Primary endpoint: estimated mean height velocity at week 52, 11.0 cm/year with somapacitan versus 9.4 with daily GH 0.035 mg/kg/day, estimated difference 1.6 cm/year (95% CI 0.91-2.23); versus 11.1 with daily GH 0.067 mg/kg/day, difference -0.1 cm/year (95% CI -0.75 to 0.60). The abstract reports noninferiority to both and superiority to the lower daily dose only. It does not supply the noninferiority margin or numerical P values. Similar safety profiles and reduced treatment burden are reported qualitatively, without adverse-event counts or burden effect estimates in the saved abstract. No claim of safety equivalence, improved adherence or final adult-height benefit is made. |
| Study Design | Original 2026 report from REAL8, NCT05330325: randomised, open-label, active-comparator phase 3 basket trial with a 52-week main phase and planned 104-week extension. This SGA substudy concerns a different indication and population from the Noonan substudy (PMID 41774755) in the same basket trial; it is not an independent replication in Noonan syndrome. Novo Nordisk employees and shareholders were among the authors. |
Expert Commentary
I regard the SGA results as encouraging evidence for a weekly regimen, with an important distinction between the two daily comparators. The first-year growth advantage applied to the lower daily dose; the higher daily dose produced a similar estimated height velocity. Describing weekly treatment as uniformly superior would therefore misrepresent the trial. Can I use this with my patients? These results can inform specialist discussions with families of treatment-naive, prepubertal children born SGA who resemble those enrolled, without establishing an individual treatment recommendation. The main limitation is that one-year growth cannot determine final adult height or delayed safety. The open-label design also matters when interpreting reported treatment burden, and qualitative safety statements should not be mistaken for demonstrated equivalence in uncommon adverse events. Manufacturer-affiliated authorship warrants transparent consideration. The SGA population must remain separate from children with Noonan syndrome: both reports belong to REAL8, but they address different indications within one basket programme, not independent replication of the same finding. Fewer injections may be attractive, yet improved adherence should not be claimed without an appropriate measured result. I would want longer indication-specific follow-up, fully quantified safety reporting and adult-height outcomes before regarding the first-year findings as a complete assessment of benefit and burden.
References
Linglart A, Böttcher V, Højby M, et al. Somapacitan in children born small for gestational age: a randomized controlled phase 3 trial. Eur J Endocrinol. 2026;194(3):311-325. doi:10.1093/ejendo/lvag021. PMID: 41782416.
